Antibiotics Market to Surpass USD 72.65 Billion by 2031, Witnessing 4.10% CAGR Growth | SkyQuest Technology

Global Antibiotics Market size was valued at USD 50.60 billion in 2022 and is poised to grow from USD 52.67 billion in 2023 to USD 72.65 billion by 2031, growing at a CAGR of 4.10% during the forecast period (2024-2031).
Antibiotics Market [https://www.skyquestt.com/report/antibiotics-market] was valued at USD 52.67 billion in 2023 to USD 72.65 billion by 2031, growing at a CAGR of 4.10% during the forecast period (2024-2031).

The antibiotics market is witnessing a dramatic surge due to the rising incidences of infectious diseases. Furthermore, the advancement of products and growing collaboration activities for the development of antibiotics are also boosting market growth. The COVID-19 pandemic has also positively influenced the development of the market. Furthermore, the profitable schemes and offers provided by the insurance firms in the form of reimbursement facilities are also immensely driving the antibiotics market. Furthermore, results which are obtained through the utilization of advanced antibiotics launched into the market by the key market are also positi8veky influencing the growth and advancement of the market. But with the increasing development of modern medicine the number of side effects have been considerably decreased which helps patients to gain confidence over the system and opt for antibiotics as a line of treatment. Antibiotics have shown immense control on infectious diseases among the people belonging to the younger age groups like children and infants. This has offered an opportunity for the growth of the market.

Get a Free Sample Research Report:https://www.skyquestt.com/sample-request/antibiotics-market

Antibiotics Market Segmental Analysis

Global Antibiotics Market is segmented by Drug Class, Type, Action Mechanism, and region.

Based on Drug Class, the market is segmented into Cephalosporin, Penicillin, Fluoroquinolone, Macrolides, Carbapenems, Aminoglycosides, Sulfonamides, 7-ACA, and Others.

Based on Type, the market is segmented into Branded Antibiotics, Generic Antibiotics.

Based on Action Mechanism, the market is segmented into Cell Wall Synthesis Inhibitors, Protein Synthesis Inhibitors, DNA Synthesis Inhibitors, RNA Synthesis Inhibitors, Mycolic Acid Inhibitors, and Others.

Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Increasing Incidences of Bacterial Infections to Propel the Market Growth

The increasing prevalence of several bacterial infections globally is one of the primary factors contributing to the growth of the market. Bacterial infections consist of Urinary Tract Infection (UTI), respiratory infections, tuberculosis, skin infections, and many more. The global burden of bacterial infections is increasing rapidly and can become the most common cause of death. A Urinary Tract Infection (UTI) is an infection in any part of the urinary system, such as kidneys, urethra, ureters, and bladder. Furthermore, resistance to various antibiotics is increasing resulting to the higher chances of infections among the general population. According to a report, published by the WHO in December 2022, increasing levels of resistance in bacteria have been reported to create life-threatening bloodstream infections. This can also lead to an increase in resistance to treatment of various bacteria which cause common infections.

Ask for Customization:https://www.skyquestt.com/speak-with-analyst/antibiotics-market

Key Players Operating in Antibiotics Market

* Pfizer Inc. (US)
* GlaxoSmithKline plc. (GSK) (UK)
* Sanofi S.A. (France)
* Merck & Co., Inc. (US)
* Novartis AG (Switzerland)
* Johnson & Johnson (US)
* F. Hoffmann-La Roche AG (Switzerland)
* AstraZeneca PLC (UK)
* Bayer AG (Germany)
* Abbott Laboratories (US)
* Eli Lilly and Company (US)
* Bristol-Myers Squibb Company (US)
* Teva Pharmaceutical Industries Ltd. (Israel)
* Astellas Pharma Inc. (Japan)
* Cipla Ltd (India)
* AbbVie, Inc. (US)
* Lupin Pharmaceuticals, Inc. (US)
* Viatris, Inc. (US)
* Melinta Therapeutics LLC (US)
* Cipla, Inc. (US)
* Shionogi & Co., Ltd. (Japan)
* KYORIN Pharmaceutical Co., Ltd. (Japan)
* Nabriva Therapeutics PLC (Ireland)

Growing Incidences of Antimicrobial Resistance to Increase Demand for New Antibiotics

There is a rise in the occurrence of antimicrobial resistance (AMR) globally, boosting the antibiotics market. AMR occurs when bacteria, viruses, parasites, or fungi develop and become resistant to the drugs utilized for treating them. It minimizes the efficiency of antibiotics and creates longer and more serious infections, increased medical expenses, and high mortality rates among individuals. Furthermore, excessive use and misuse of antibiotics are supporting the development of drug-resistant bacteria, which makes conventional antibiotics less efficient. Moreover, multidrug-resistant strains, like Methicillin-resistant Staphylococcus aureus (MRSA) and Carbapenem-resistant Enterobacteriaceae (CRE), are more predominant. This requires the development of new antibiotics or substitute treatments to fight against these resistant strains.

* In March 2024, Wockhardt made an announcement that its antibiotic under-trial drug offered successful result. Zidebactam/Cefepime can be used for treating a highly drug-resistant skull bone infection and pneumonia in a renal transplant patient.
* In January 2024, European Medicines Agency approved Orchid Pharma's Exblifeb. This drug can be utilized in the treatment of pneumonia, urinary tract infections (UTI), and others.
* In September 2023, Appili Therapeutics, received the U.S. FDA approval for its liquid oral form of antibiotic drug metronidazole.

View report summary and Table of Contents (TOC): https://www.skyquestt.com/report/antibiotics-market

This Market Consists of the Following Insights

Drug Class

PenicillinMacrolides

Type

Branded Antibiotics

Generic Antibiotics

Action Mechanism

Protein Synthesis Inhibitors

Cell Wall Synthesis Inhibitors

Technological Advancements in Antibiotics to Increase Efficiency

Developments in biotechnology, molecular biology, and drug discovery techniques helps in enhancing the efficiency and efficacy of antibiotic development. Genomics and high-throughput screening helps in the detection of possible drug targets and the screening of large compound libraries. Furthermore, computer-aided drug design allows to analyse the effectiveness of drug and improves antibiotic candidates. These technological advancements smoothen the antibiotic discovery procedure and decrease the time and expense related to conventional methods. Moreover, developments in diagnostic techniques, like rapid pathogen identification and susceptibility testing, help to select accurate antibiotic that offers better patient outcomes. Furthermore, technological advancements help in the advancement of new and more potent antibiotics to cure infectious diseases and antimicrobial resistance.

Visit Our Website: https://www.skyquestt.com/

Media Contact
Company Name: Skyquest Technology
Contact Person: Mr. Jagraj Singh
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=antibiotics-market-to-surpass-usd-7265-billion-by-2031-witnessing-410-cagr-growth-skyquest-technology]
Phone: +1 351-333-4748
Address:1 Apache Way, Westford,
Country: United States
Website: https://www.skyquestt.com/report/antibiotics-market



This release was published on openPR.